弗朗西斯科·Dazzi -澳门在线赌城娱乐

我是澳门第一赌城在线娱乐研发部的医学主管&D for Cell Therapies where I am responsible for guiding our strategies for cell therapy clinical applications. Our cross-functional team takes the biology to accelerate the delivery of new cell therapies to patients. A major part of my role is to collaborate closely with internal and external experts in the cell therapy field and related disciplines. 在澳门在线赌城娱乐, 这适用于所有的治疗领域, 利用现有的和新兴的干细胞技术平台, 新模式, 通用细胞系和crispr介导的基因组编辑.

Externally, 我与现有的合作者合作，并建立新的合作伙伴关系, to develop technologies and cellular therapeutic projects that will discover novel treatments for serious diseases and advance these towards patients.

I bring expertise in biology and clinical applications of cell therapies in stem cell transplantation. 在90年代末, 我建立了一个非常成功的白血病免疫细胞治疗方案, 我开发的疗法已经被国际上采用. Based on my subsequent discovery that mesenchymal stromal cells (MSC) exhibit immunomodulatory activities, I curated a nationwide clinical programme for the use of these cells to control unwanted immune responses in transplantation. 通过揭示这些免疫调节反应的潜在机制, I have also identified a biomarker to stratify patients for MSC treatment and a new methodology to generate more effective MSC.

1984年从帕多瓦大学毕业后, 在获得实验肿瘤学博士学位之前，我是一名血液肿瘤学家. In 1996, I moved to the Royal Postgraduate Medical School (now part of Imperial College London) and in 2007 was appointed as Chair of Stem Cell Biology. 六年后, I joined 伦敦大学国王学院 as Professor of Regenerative Medicine and Lead of Cellular Therapies. 国王学院是全欧洲该领域最大的项目之一.

The opportunity for cell therapies to radically improve human health and transform patient outcomes continues to drive my motivation. 澳门第一赌城在线娱乐处于这项技术的前沿, 凭借澳门第一赌城在线娱乐在疾病生物学方面的专业知识以及基因编辑方面的重大创新, 蛋白质工程与细胞培养技术.

弗朗西斯科·Dazzi 医疗铅细胞疗法，澳门第一赌城在线娱乐R&D、澳门在线赌城娱乐

范鲁德奖，2018年

《澳门在线赌城娱乐》最佳论文，欧洲血液和骨髓移植学会

2005年“最佳摘要”奖

Best abstract award for basic science research at the Annual Meeting of the American Society for Blood and Marrow Transplantation

斯托克顿奖，1999年

Best oral presentation at the 25th Annual Meeting of the European Group for Blood and Marrow Transplantation

2014-2022

Served as Professor of Regenerative and Haematological Medicine and Vice-Dean (International) for Faculty of Life Sciences and Medicine, 伦敦大学国王学院, and developed a highly successful mechanistic biomarker to stratify patients for treatment with mesenchymal stromal cells for severe graft-versus-host disease.

2006-2012

During my time at Imperial College London as Professor of Stem Cell Biology and Honorary Consultant Haematologist, I developed the clinical immunotherapy programme for haematological malignancies and coordinated the GMP facility to manufacture and distribute mesenchymal stromal cells to several Transplantation Centres across the UK.

1991-1996

在我的职业生涯中, I am motivated by my time as a consultant haematologist at the University of Padova – with the patient and recognising the promise of making a difference.

科学出版物

Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhauser米, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. 血液骨髓移植. 2018 Jul 19. pii: s1083 - 8791 (18) 30402 - 6

费雷拉SA, Motwani MS, Faull PA, Seymour AJ, Yu TTL, Enayati M, Taheem DK, Salzlechner C, Haghighi T, Kania EW, Oommen P, Ahmed T, Parzych K, Dazzi F， Festy F, Grigoriadis AE, Auner HW, Snijders AP, Bozec L & 绅士E. 自然的交流, 2018 s41467-018-06183-4

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, 理查森D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley摩根富林明, Dazzi F. 英国血液学杂志. 2019 Jan 13. doi: 10.1111/bjh.15749

张ts, Galleu A, 冯·博宁, Bornhauser米， Dazzi F. Haematologica, 2019; 104:e441-2

Petrova A, Georgiadis C, Fleck RA, Allison L, McGrath JA， Dazzi F，迪维利，卡西姆·维. 皮肤病学研究杂志， 2019，工程物理学报(英文版):32535-7

Uccelli A和 MESEMS study group. Trials2019年5月9日;20(1):263

Devito L, Klontzas ME, Cvoro A, Galleu A, Simon M, Hobbs C， Dazzi F， Mantalaris A, Khalaf Y, Ilic D. Cell Death & Disease[j]， 2019年3月20日;10(4):277

Dazzi F, Szydlo RM, Craddock C, Cross NCP, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley摩根富林明, Goldman JM. Blood. 95(1):67-71, 2000.

Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, and Dazzi F. Blood 101:3722-9, 2003

Rashidghamat E, Kadiyirire T, Ayis S, Petrof G, Liu L, Pullabhatla V, Ainali C, Guy A, Aristodemou年代, McMillan J, Ozoemena L, Mee J, Pramanik R, Saxena A, Nuamah R, de Rinaldis E, Serrano S, Maurin C, Martinez-Queipo米, Lwin S, Ilic D, Martinez A, Dazzi F, Slaper-Cortenbach I, Westinga K, Zeddies S, van den Broek M, Onoufriadis A, Mellerio J, McGrath JA. 美国皮肤病学会杂志, 2019

加略·A·里夫-巴斯克斯·Y, Trento C, Lomas C, Dolcetti L,Cheung TS, 冯·博宁, Barbieri L, Halai K, Ward S, Weng L, Chakraverty R, LombardiG, Watt FM, Orchard K, Marks DI, Apperley J, Bornhauser米, Walczak H, Bennett C,and Dazzi F. Science Translational medicine, 2017, vol . 9, Issue 416, eaam7828

Veeva ID: Z4-52653
编制日期:2023年2月

范鲁德奖，2018年

2005年“最佳摘要”奖

斯托克顿奖，1999年

科学出版物

Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey amongst centers affiliated to the European Group of Blood and Marrow Transplantation

双向细胞-细胞外基质相互作用直接影响干细胞的命运

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival

Apoptotic mesenchymal stromal cells induce prostaglandin E2 in monocytes: implications for the monitoring of mesenchymal stromal cell activity

Human mesenchymal stromal cells engineered to express collagen VII can restore anchoring fibrils in recessive dystrophic epidermolysis bullosa skin graft chimeras

间充质干细胞治疗多发性硬化症(MESEMS):一项随机研究, 双盲, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Comparison of human isogeneic Wharton's jelly MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG stimulation

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allograft for chronic myeloid leukaemia.

Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide.

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Perforin-dependent apoptosis in mesenchymal stromal cells is required to initiate host-mediated in vivoimmunomodulation.